New Drug Target Found for CCDC112, A Protein Involved in Prostate and Bladder Cancer

Target Name: CCDC112

NCBI ID: G153733

CCDC112

New Drug Target Found for CCDC112, A Protein Involved in Prostate and Bladder Cancer

CCDC112 is a protein that is expressed in a variety of tissues, including the bladder, and has been shown to be involved in the development and progression of prostate and bladder cancers. Researchers have now identified a potential drug target for this protein, which could lead to new treatments for these deadly diseases.

The protein CCDC112 is a member of the carbohydrate-rich glycoprotein (CRG) family, which is characterized by the presence of a carbohydrate moiety on the protein's N-terminus. CCDC112 is expressed in a variety of tissues, including the bladder, prostate, and lymphoid organs.

In addition to its expression in cancer cells, CCDC112 has also been shown to be involved in the development and progression of prostate and bladder cancers. For example, studies have shown that high levels of CCDC112 are associated with poor prognosis in patients with prostate cancer, and that blocking this protein may inhibit the growth and spread of these tumors.

Researchers have now identified a potential drug target for CCDC112, which is located on the protein's C-terminus. This target is called CSN-1, and is a protein that is expressed in a variety of tissues, including the bladder, lymphoid organs, and brain.

Studies have shown that CSN-1 is involved in the regulation of cell survival and growth, and that it plays a role in the development and progression of cancer. By blocking CSN-1, researchers hope to inhibit the growth and spread of prostate and bladder cancer cells.

In addition to its potential as a drug target, CCDC112 has also been identified as a potential biomarker for prostate and bladder cancer. This is because the protein is often expressed in high levels in cancer cells, and can be used as a protein biomarker for these diseases.

Research into CCDC112 and its potential as a drug target is still in its early stages, but it holds great promise as a new treatment for prostate and bladder cancer. As further studies are conducted, researchers hope to learn more about the protein's role in cancer development and progression, and to develop new treatments based on this information.

Protein Name: Coiled-coil Domain Containing 112

The "CCDC112 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC112 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets